Sub Heading

Clinical Trials Details

An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer

IRB Protocol Number
SGNTUC-029

Clinical Trial Categories

  • Colorectal Cancer
Contact
Clinical Trials at 910-715-2200
How to Participate

Eligibility: Men and women age 18 and older with HER2+ metastatic colorectal cancer

Contact Us

For more information on participating in a clinical trial, contact us at 910-715-2200 or talk to your doctor.